ReviewCancer reports (Hoboken, N.J.)2023
Overview of glottic laryngeal cancer treatment recommendation changes in the NCCN guidelines from 2011 to 2022.
Review in Cancer reports (Hoboken, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Dosimetric Evaluation of MR-Guided IMRT and VMAT Techniques for Early-Stage Glottic Cancer: A Pilot Comparative Planning Study.Medicina (Kaunas, Lithuania) · 2026Article
- Bridging the gap: modern pharyngolaryngoesophagectomy techniques and the rise of neoadjuvant/immunotherapy approaches.World journal of surgical oncology · 2026Review
- Diagnostic value of MRI for posttreatment surveillance of early-stage (I-II) glottic larynx cancer.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- Transoral laser microsurgery and open partial laryngectomy for limited-stage glottic cancer: a review of indications, oncologic and functional outcome, and prognosis.American journal of translational research · 2026Review
- Low-temperature plasma radiofrequency ablation is effectively treats early glottic carcinoma.American journal of translational research · 2026Article
- Low expression of HSP27 and HSP70 predicts poor prognosis in laryngeal squamous cell carcinoma.Journal of cancer research and clinical oncology · 2025Article
- VEGFA (rs1570360, rs699947, rs3025033, rs2146323, rs3024997) genotypes in patients with laryngeal squamous cell carcinoma.BMC cancer · 2025Article
- Article
- Clinical Outcomes of Curative Intent Radiotherapy by Helical Tomotherapy for Laryngeal Squamous Cell Carcinoma: A Retrospective Analysis in a Tertiary Referral Center.World journal of oncology · 2024Article
- Long-term efficacy of transoral endoscopic plasma resection in the treatment of early glottic laryngeal cancer and analysis of prognostic factors.American journal of cancer research · 2024Article
- Overview of glottic laryngeal cancer treatment recommendation changes in the NCCN guidelines from 2011 to 2022.Cancer reports (Hoboken, N.J.) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe treatment of glottic cancer remains challenging, especially with regard to morbidity reduction and larynx preservation rates. The National Comprehensive Cancer Network (NCCN) has published guidelines to aid decision-making about this treatment according to the tumor site, clinical stage, and patient medical status.
aimThe present review was conducted to identify changes in the NCCN guidelines for glottic cancer treatment made between 2011 and 2022 and to describe the published evidence concerning glottic cancer treatment and oncological outcomes in the same time period. METHODS AND
resultsClinical practice guidelines for head and neck cancer published from 2011 up to 2022 were obtained from the NCCN website (www.NCCN.org). Data on glottic cancer treatment recommendations were extracted, and descriptive analysis was performed. In addition, a review of literature registered in the PubMed database was performed to obtain data on glottic cancer management protocols and treatment outcomes from randomized controlled trials, systematic reviews, and meta-analyses published from 2011 to 2022. In total, 24 NCCN guidelines and updates and 68 relevant studies included in the PubMed database were identified. The main guideline changes made pertained to surgical and systemic therapies, the consideration of adverse features, and new options for the treatment of metastatic disease at initial presentation. Early-stage glottic cancer received the most research attention, with transoral endoscopic laser surgery and radiotherapy assessed and compared as the main treatment modalities. Reported associations between treatment types and survival rates for this stage of glottic cancer appear to be similar, but functional outcomes can be highly compromised.
conclusionNCCN panel members provide updated recommendations based on currently accepted treatment approaches for glottic cancer, constantly reviewing new surgical and non-surgical techniques. The guidelines support decision-making about glottic cancer treatment that should be individualized and prioritize patients' quality of life, functionality, and preferences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.